New York, NY -- (SBWIRE) -- 01/21/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Earthlink Holdings Corp (NASDAQ:ELNK), Abraxas Petroleum Corp (NASDAQ:AXAS), Solta Medical Inc (NASDAQ:SLTM), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Earthlink Holdings Corp (NASDAQ:ELNK) showed a volume of 1.08 million shares by the end of last trade whereas the average volume of the stock remained 1.08 million shares. The stock opened the session at $4.95 but then moved to $4.83. At that price, the stock showed a negative performance of -2.23%. EarthLink Holdings Corp, formerly EarthLink, Inc., is a network, communications and information technology (IT) services provider to business and residential customers in the United States. The Company operates in two segments: Business Services and Consumer Services.
Will ELNK Get Buyers Even After The Recent Rally? Find Out Here
Abraxas Petroleum Corp (NASDAQ:AXAS) opened the session at $3.18 and closed the session at $3.27. The stock showed a positive performance of 3.48% in previous trading session. Traded with volume of 1.07 million shares in the prior session and the average volume of the stock remained 1.14 million shares. Abraxas Petroleum Corporation is an independent energy company primarily engaged in the acquisition, exploitation, development and production of oil and gas in the United States and Canada.
For How Long AXAS will fight for Profitability? Read This Trend Analysis report
Solta Medical Inc (NASDAQ:SLTM) opened the session at $2.92 and closed the session at $2.92. The stock showed a negative performance of -0.34% in previous trading session. Traded with volume of 1.07 million shares in the prior session and the average volume of the stock remained 2.37 million shares. The beta of the stock remained 2.70. Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications.
Why Should Investors Buy SLTM After the Recent Fall? Just Go Here and Find Out
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) the stock decreased -0.65% and finished the session at $6.13. Traded with volume of 1.05 million shares in the prior session and the average volume of the stock remained 2.17 million shares. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Will MACK Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)